Brief: Innovative Pharmaceutical Biotech Entered Into MoU With Conflux Hong Kong Management
06/05/2025 16:21
May 6 (Reuters) - Innovative Pharmaceutical Biotech Ltd 0399.HK: ENTERED INTO MOU WITH CONFLUX HONG KONG MANAGEMENT MOU FOR COOPERATION ON INFRASTRUCTURE AND COMMON KEY TECHNOLOGIES RELATED TO CONFLUX BLOCKCHAIN Further company coverage: 0399.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Starcoin
See all newsBrief: Starcoin Group Says Trading In Shares Of Co Will Suspend From 6 May
Brief: Starcoin Enters Non-Binding Memorandum Of Understanding With Marvel Nice
Brief: Starcoin Group Enters MoU For Strategic Cooperation With Huamei Haibo Biotechnology (Chongqing)
Brief: Starcoin Group Says Unit, Others Enters Deal For Brazilian Gold Mine RWA Tokenization
Brief: Starcoin Group, Newbridge And Conflux Foundation Entered MoU